Non-neoplastic advanced lung disease /
Saved in:
| Imprint: | New York : Marcel Dekker, c2003. |
|---|---|
| Description: | xix, 817 p. : ill. ; 24 cm. |
| Language: | English |
| Series: | Lung biology in health and disease ; v. 176 |
| Subject: | |
| Format: | Print Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/4882799 |
Table of Contents:
- Introduction
- Preface
- Contributors
- Part 1. Pathology of Advanced Lung Disease
- 1.. Pathology of Advanced Obstructive Lung Disease: Emphysema, Chronic Bronchitis, Bronchiolitis Obliterans, Bronchiectasis
- I.. Introduction
- II.. Emphysema
- III.. Chronic Bronchitis
- IV.. Bronchiolitis Obliterans
- V.. Bronchiectasis
- References
- 2.. Pathology of Advanced Interstitial Diseases: Pulmonary Fibrosis, Sarcoidosis, Pulmonary Histiocytosis X, Autoimmune Pulmonary Disease, and Lymphangioleiomyomatosis
- I.. Introduction
- II.. Pulmonary Fibrosis
- III.. Sarcoidosis
- IV.. Pulmonary Histiocytosis X (Eosinophilic Granuloma, Langerhans Cell Granulomatosis of the Lung)
- V.. Autoimmune Pulmonary Disease
- VI.. Lymphangioleiomyomatosis
- References
- 3.. Pathology of Advanced Pulmonary Vascular Disease
- I.. Introduction
- II.. Systemic-to-Pulmonary Shunts
- III.. Primary Pulmonary Arterial Hypertension
- IV.. Chronic Pulmonary Thrombotic and/or Embolic Disease
- V.. Pulmonary Veno-occlusive Disease
- VI.. Pulmonary Capillary Hemangiomatosis
- VII.. Lung Biopsy in Advanced Pulmonary Vascular Disease
- VIII.. Risks and Benefits of Lung Biopsy
- References
- Part 2. Rest and Exercise Physiology in Advanced Lung Disease
- 4.. Management of Advanced Advanced Chronic Obstructive Pulmonary Disease
- I.. Introduction
- II.. Pathophysiology of Exercise Intolerance in COPD
- III.. Assessment of the Dyspneic Patient
- IV.. Management
- V.. Oxygen Therapy
- VI.. Case Summary
- VII.. Adjunctive Therapies
- VIII.. Management of Acute Exacerbation of COPD
- IX.. Summary
- References
- 5.. Role of Physiological Assessment in Advanced Interstitial Lung Disease
- I.. Physiological Abnormalities
- II.. Clinical Applications
- III.. Idiopathic Pulmonary Fibrosis
- IV.. Collagen Vascular Diseases
- V.. Rheumatoid Arthritis
- VI.. Polymyositis and Dermatomyositis
- VII.. Overlap Syndrome and Mixed Connective Tissue Disease
- VIII.. Sjogren's Syndrome
- IX.. Sarcoidosis
- X.. Pulmonary Function Tests in Sarcoidosis
- XI.. Langerhans Cell Histiocytosis (Pulmonary Eosinophilic Granuloma)
- XII.. Summary
- References
- 6.. Pulmonary Vascular Disease
- I.. Introduction
- II.. Physiology of the Normal Pulmonary Vascular Bed
- III.. Pathophysiology of the Pulmonary Vascular Bed
- IV.. Physiology of Exercise in Pulmonary Vascular Disease
- V.. Conclusion
- References
- Part 3. Medical Management
- 7.. Management of Nonbronchiectatic Chronic Obstructive Pulmonary Disease
- I.. Goals of Therapy
- II.. Assessing and Monitoring Disease
- III.. Medical Management of the Stable Patient with COPD
- IV.. Medical Management of the COPD Patient During an Exacerbation
- V.. Conclusion
- References
- 8.. Management of Bronchiectasis and Cystic Fibrosis
- I.. Overview
- II.. Bronchiectasis: An Introduction
- III.. Pathology
- IV.. Pathophysiology
- V.. Etiology
- VI.. Focal Bronchiectasis
- VII.. Diffuse Bronchiectasis
- VIII.. Clinical Features
- IX.. Cystic Fibrosis: An Introduction
- X.. Pathogenesis
- XI.. Current Medical Management of CF
- XII.. Medical Management of CF Airways Disease
- XIII.. The Future
- XIV.. Summary
- References
- 9.. Pulmonary Interstitial Disease: Idiopathic, Autoimmune, and Drug-Related
- I.. Introduction
- II.. Interstitial Lung Disease in Connective Tissue Disorders
- III.. Drug-Induced Pulmonary Disease
- IV.. Drug Therapy for UIP/IPF
- V.. Management of Patients with Advanced Pulmonary Fibrosis
- References
- 10.. Sarcoidosis, Lymphangioleiomyomatosis, and Histiocytosis
- I.. Sarcoidosis
- II.. Lymphangioleiomyomatosis
- III.. Langerhans Cell Histocytosis
- References
- 11.. Medical Management of Pulmonary Vascular Disease
- I.. Introduction
- II.. General Measures
- III.. Anticoagulation
- IV.. Oxygen
- V.. Cardiac Glycosides and Diuretics
- VI.. Vasodilators
- VII.. Calcium Channel Blockers
- VIII.. Prostaglandins
- IX.. Endothelin Receptor Antagonists
- X.. Nitric Oxide
- XI.. The Future
- XII.. Conclusion
- References
- Part 4. Surgical Management
- 12.. Lung Volume Reduction Surgery
- I.. Introduction
- II.. Pathophysiological Basis for Lung Volume Reduction Surgery
- III.. History of Lung Volume Reduction Surgery
- IV.. Outcome of Lung Volume Reduction Surgery
- V.. Techniques of Lung Volume Reduction Surgery
- VI.. Physiological Mechanisms of Improvement with Lung Volume Reduction Surgery
- VII.. Complications of Lung Volume Reduction Surgery
- VIII.. Patient Selection
- IX.. Summary
- References
- 13.. Pulmonary Thromboendarterectomy
- I.. Introduction
- II.. Historical Perspective
- III.. Natural History
- IV.. Clinical Presentation
- V.. Diagnostic Evaluation
- VI.. Pulmonary Thromboendartectomy
- VII.. Postoperative Care
- VIII.. Outcome Following Pulmonary Thromboendartectomy
- IX.. Future Directions
- References
- 14.. Lung Transplantation
- I.. History
- II.. Indications
- III.. Surgical Options
- IV.. Complications
- V.. Outcomes
- References
- Part 5. Incidence and Management of Medical Comorbidities
- 15.. Comorbidities in Advanced Lung Disease
- I.. Introduction
- II.. Impact of Comorbidities
- III.. Cardiac and Vascular Comorbidities
- IV.. Pulmonary Embolism
- V.. Gastroesophageal Reflux Disease
- VI.. Cancer
- VII.. Cognitive Functioning
- VIII.. Summary
- References
- 16.. Osteoporosis and Metabolic Bone Disease and Endocrine Abnormalities
- I.. Overview
- II.. Osteoporosis
- III.. Osteoporosis: Presentation
- IV.. Osteoporosis: Diagnostic Approach
- V.. Osteoporosis: Management and Therapy
- VI.. Osteoporosis in Chronic Obstructive Pulmonary Disease
- VII.. Osteoporosis in Asthma
- VIII.. Osteoporosis in Cystic Fibrosis
- IX.. Osteoporosis in Sarcoidosis
- X.. Osteoporosis in Lymphangioleiomyomatosis
- XI.. Endocrine Abnormalities
- XII.. Langerhans Cell Histiocytosis (Eosinophilic Granuloma)
- XIII.. Wegener's Granulomatosis
- XIV.. Bronchiolitis Obliterans Organizing Pneumonia
- XV.. Pulmonary Hypertension
- XVI.. Hypogonadism
- References
- 17.. Cachexia in Chronic Obstructive Pulmonary Disease
- I.. Introduction
- II.. Prevalence of Cachexia in COPD
- III.. Underlying Factors of Cachexia in COPD
- IV.. Consequences of Cachexia in COPD
- V.. Treatment of Cachexia in COPD
- References
- Part 6. Psychosocial Management and Quality of Life
- 18.. Anxiety, Depression, and Coping Skills
- I.. Introduction
- II.. Enhancing Coping Strategies in Distressed Patients
- III.. Anxiety and Anxiety Disorders
- IV.. Panic Attacks and Panic Disorder
- V.. Generalized Anxiety Disorder
- VI.. Adjustment Disorder with Anxious Mood
- VII.. Posttraumatic Stress Disorder
- VIII.. Management
- IX.. Depression and Depressive Disorders
- X.. Conclusions
- References
- 19.. Measurement of Health Status in Advanced Respiratory Disease
- I.. What Is Health-Related Quality of Life? What Is Health Status?
- II.. Measurement Criteria
- III.. Types of Health Status Questionnaires
- IV.. Minimal Important Difference
- V.. Clinical Applications
- VI.. Summary
- References
- 20.. Traveling with Supplemental Oxygen for Patients with Chronic Lung Disease
- I.. Introduction
- II.. Environment Oxygen at Altitude and in Aircraft
- III.. Physiological Consequences of Air Travel
- IV.. Risks of Air Travel
- V.. Assessment of In-Flight Oxygenation
- VI.. Fitness to Fly and Oxygen Supplementation
- VII.. Practical Considerations
- VIII.. Future Directions
- IX.. Summary
- References
- 21.. Advanced Lung Disease: End-of-Life Care
- I.. Introduction
- II.. Attributes of a Good Death
- III.. Prognosis
- IV.. Advance Medical Planning
- V.. Hospice Home Care
- VI.. Dying at Home
- References
- Author Index
- Subject Index
